raloxifene ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives 2351 84449-90-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • raloxifene
  • keoxifene
  • raloxifene hydrochloride
  • evista
  • raloxifene HCl
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
  • Molecular weight: 473.59
  • Formula: C28H27NO4S
  • CLOGP: 6.86
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 2
  • TPSA: 70
  • ALOGS: -5.97
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.12 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 2 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 7.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 5, 1998 EMA ELI LILLY NEDERLAND B.V.
Dec. 9, 1997 FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endometrial cancer 256.13 12.17 77 20265 3148 63465532
Breast cancer 236.54 12.17 163 20179 48220 63420460
Deep vein thrombosis 171.10 12.17 170 20172 83630 63385050
Retinal vein thrombosis 143.67 12.17 33 20309 457 63468223
Bone density decreased 137.84 12.17 75 20267 14537 63454143
Pulmonary embolism 136.08 12.17 177 20165 116507 63352173
Fracture 114.99 12.17 74 20268 19510 63449170
Femur fracture 110.70 12.17 98 20244 41658 63427022
Spinal compression fracture 104.25 12.17 62 20280 14221 63454459
Retinal vein occlusion 84.02 12.17 30 20312 2113 63466567
Hip fracture 81.77 12.17 71 20271 29403 63439277
Transient ischaemic attack 72.22 12.17 74 20268 37679 63431001
Body height decreased 71.60 12.17 43 20299 10035 63458645
Cerebral infarction 71.26 12.17 60 20282 23833 63444847
Fall 70.53 12.17 280 20062 392054 63076626
Thoracic vertebral fracture 68.04 12.17 32 20310 4560 63464120
Compression fracture 66.13 12.17 35 20307 6413 63462267
Pelvic fracture 65.22 12.17 45 20297 13303 63455377
Drug ineffective 63.58 12.17 152 20190 1044613 62424067
Breast cancer in situ 62.50 12.17 22 20320 1486 63467194
Breast cancer female 62.26 12.17 44 20298 13515 63455165
Lumbar vertebral fracture 58.07 12.17 31 20311 5779 63462901
Cerebrovascular accident 57.86 12.17 115 20227 107909 63360771
Oestrogen receptor assay positive 57.45 12.17 16 20326 496 63468184
Spinal fracture 56.80 12.17 47 20295 18224 63450456
Visual acuity reduced 53.43 12.17 49 20293 21777 63446903
Osteonecrosis of jaw 53.42 12.17 61 20281 35062 63433618
Off label use 53.16 12.17 84 20258 674378 62794302
Infusion related reaction 50.27 12.17 9 20333 245512 63223168
Product use issue 49.96 12.17 6 20336 220514 63248166
Toxicity to various agents 48.64 12.17 10 20332 247240 63221440
Low turnover osteopathy 46.59 12.17 24 20318 4161 63464519
Systemic lupus erythematosus 44.22 12.17 7 20335 208911 63259769
Ovarian cancer 43.75 12.17 26 20316 5950 63462730
Osteonecrosis 43.17 12.17 46 20296 24484 63444196
Synovitis 42.55 12.17 5 20337 186913 63281767
Endometrial cancer stage I 42.51 12.17 11 20331 256 63468424
Wrist fracture 42.33 12.17 35 20307 13552 63455128
Postmenopausal haemorrhage 41.50 12.17 18 20324 2124 63466556
Hot flush 41.00 12.17 65 20277 51094 63417586
Muscle spasms 40.55 12.17 126 20216 156024 63312656
Glossodynia 40.18 12.17 5 20337 178871 63289809
Treatment failure 39.24 12.17 8 20334 199035 63269645
Product complaint 37.84 12.17 32 20310 12777 63455903
Myocardial infarction 37.23 12.17 92 20250 99801 63368879
Drug intolerance 36.97 12.17 27 20315 308634 63160046
Retinal vascular thrombosis 36.17 12.17 9 20333 178 63468502
Uterine cancer 35.72 12.17 21 20321 4712 63463968
Blindness unilateral 35.19 12.17 23 20319 6218 63462462
Rheumatoid arthritis 33.36 12.17 20 20322 253799 63214881
Uterine polyp 32.59 12.17 15 20327 2035 63466645
Cataract 32.05 12.17 62 20280 56991 63411689
Alopecia 30.52 12.17 38 20304 337498 63131182
Therapeutic product effect decreased 30.27 12.17 12 20330 193175 63275505
Oedema peripheral 29.80 12.17 130 20212 189381 63279299
Endometrial cancer stage II 28.83 12.17 5 20337 13 63468667
Pericarditis 28.77 12.17 4 20338 131575 63337105
Multiple fractures 28.53 12.17 23 20319 8595 63460085
Hyperlipidaemia 28.09 12.17 33 20309 19538 63449142
Stress fracture 27.96 12.17 22 20320 7941 63460739
Intentional product use issue 27.70 12.17 4 20338 127888 63340792
Rib fracture 27.41 12.17 35 20307 22562 63446118
Retinal haemorrhage 27.26 12.17 18 20324 4951 63463729
Therapeutic product effect incomplete 26.88 12.17 4 20338 125052 63343628
Intestinal pseudo-obstruction 25.62 12.17 10 20332 902 63467778
Lumbar spinal stenosis 25.32 12.17 17 20325 4805 63463875
Lower respiratory tract infection 24.69 12.17 6 20336 132301 63336379
Back pain 24.16 12.17 156 20186 263989 63204691
Injection site haemorrhage 23.91 12.17 34 20308 24280 63444400
Embolism 23.87 12.17 20 20322 7886 63460794
Joint swelling 22.81 12.17 44 20298 327622 63141058
Wound 22.68 12.17 12 20330 163251 63305429
Femoral neck fracture 22.56 12.17 20 20322 8503 63460177
Hepatic enzyme increased 22.56 12.17 19 20323 202309 63266371
Ischaemic stroke 22.07 12.17 28 20314 17929 63450751
Breast cancer recurrent 22.07 12.17 15 20327 4326 63464354
Swelling 21.88 12.17 34 20308 275344 63193336
Thrombosis 21.39 12.17 57 20285 64698 63403982
Embolism venous 21.22 12.17 13 20329 3141 63465539
General physical health deterioration 21.15 12.17 20 20322 201382 63267298
Oestrogen receptor assay negative 21.14 12.17 3 20339 0 63468680
Pain 21.09 12.17 145 20197 740483 62728197
Product use in unapproved indication 20.99 12.17 16 20326 179064 63289616
Peripheral swelling 20.97 12.17 33 20309 265909 63202771
Dementia Alzheimer's type 20.84 12.17 9 20333 1051 63467629
Intramedullary rod insertion 20.30 12.17 11 20331 2112 63466568
Diverticulum 20.24 12.17 22 20320 11969 63456711
Bone pain 20.00 12.17 50 20292 54591 63414089
Osteopenia 19.94 12.17 28 20314 19757 63448923
Fibrocystic breast disease 19.82 12.17 9 20333 1183 63467497
Feeling abnormal 19.77 12.17 97 20245 148295 63320385
Spinal osteoarthritis 19.52 12.17 25 20317 16161 63452519
Psoriatic arthropathy 19.50 12.17 3 20339 91517 63377163
Uterine leiomyoma 19.36 12.17 19 20323 9179 63459501
Endometrial hyperplasia 19.05 12.17 8 20334 872 63467808
Infection 18.48 12.17 28 20314 229145 63239535
Fractured sacrum 18.05 12.17 10 20332 2006 63466674
Humerus fracture 18.00 12.17 18 20324 8898 63459782
Helicobacter infection 17.72 12.17 4 20338 92781 63375899
Blood calcium increased 17.28 12.17 18 20324 9332 63459348
Colitis ischaemic 16.96 12.17 19 20323 10689 63457991
Fracture nonunion 16.84 12.17 10 20332 2285 63466395
Coronary artery disease 16.75 12.17 34 20308 32343 63436337
Colon cancer 16.46 12.17 18 20324 9860 63458820
Musculoskeletal stiffness 16.44 12.17 21 20321 184597 63284083
Intervertebral disc protrusion 16.13 12.17 28 20314 23681 63444999
Foot fracture 15.96 12.17 28 20314 23886 63444794
Kyphosis 15.90 12.17 10 20332 2530 63466150
Insulinoma 15.89 12.17 4 20338 83 63468597
Thrombotic stroke 15.56 12.17 6 20336 524 63468156
Breast swelling 15.47 12.17 8 20334 1398 63467282
Pleurisy 15.31 12.17 16 20326 8324 63460356
Vision blurred 15.15 12.17 64 20278 91860 63376820
Jaw disorder 15.06 12.17 13 20329 5336 63463344
Radius fracture 14.87 12.17 11 20331 3624 63465056
Endometrial hypertrophy 14.59 12.17 5 20337 312 63468368
Gastrooesophageal reflux disease 14.55 12.17 65 20277 95574 63373106
Pathological fracture 14.55 12.17 16 20326 8818 63459862
Haemorrhage subcutaneous 14.44 12.17 10 20332 2973 63465707
Lung neoplasm malignant 14.44 12.17 24 20318 19609 63449071
Erythema multiforme 14.35 12.17 17 20325 10152 63458528
Gastrointestinal tract adenoma 14.27 12.17 5 20337 333 63468347
Osteomyelitis 14.27 12.17 28 20314 25992 63442688
Bone disorder 14.27 12.17 25 20317 21301 63447379
Drug abuse 14.10 12.17 3 20339 72515 63396165
Subacute hepatic failure 14.07 12.17 4 20338 134 63468546
Glaucoma 13.75 12.17 23 20319 18882 63449798
Atrophic vulvovaginitis 13.75 12.17 8 20334 1760 63466920
Altered state of consciousness 13.65 12.17 27 20315 25203 63443477
Sarcoma uterus 13.53 12.17 3 20339 35 63468645
Tibia fracture 13.52 12.17 12 20330 5108 63463572
Abdominal discomfort 13.46 12.17 55 20287 320830 63147850
Breast calcifications 13.28 12.17 7 20335 1271 63467409
Exostosis of jaw 13.23 12.17 7 20335 1282 63467398
Visual field defect 12.79 12.17 13 20329 6548 63462132
Ligament sprain 12.73 12.17 18 20324 12782 63455898
Intentional overdose 12.64 12.17 4 20338 74148 63394532
Atrial fibrillation 12.62 12.17 72 20270 116564 63352116
Intervertebral disc degeneration 12.61 12.17 20 20322 15712 63452968
Vascular headache 12.54 12.17 3 20339 50 63468630
Osteoporotic fracture 12.40 12.17 10 20332 3736 63464944
Acute myocardial infarction 12.40 12.17 30 20312 32094 63436586
Hypersensitivity 12.38 12.17 50 20292 292635 63176045
Aortic aneurysm 12.18 12.17 10 20332 3834 63464846

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endometrial cancer 160.54 13.04 43 14509 2051 79727785
Bone density decreased 125.25 13.04 57 14495 13290 79716546
Breast cancer 111.28 13.04 72 14480 33709 79696127
Retinal vein thrombosis 107.60 13.04 25 14527 660 79729176
Deep vein thrombosis 105.61 13.04 120 14432 120799 79609037
Spinal compression fracture 97.90 13.04 52 14500 16906 79712930
Femur fracture 82.11 13.04 63 14489 38589 79691247
Thoracic vertebral fracture 81.25 13.04 32 14520 5221 79724615
Pulmonary embolism 76.85 13.04 123 14429 171531 79558305
Oestrogen receptor assay positive 73.39 13.04 16 14536 314 79729522
Body height decreased 72.26 13.04 34 14518 8546 79721290
Fracture 68.20 13.04 45 14507 21756 79708080
Breast cancer female 62.94 13.04 34 14518 11427 79718409
Hip fracture 60.69 13.04 48 14504 30713 79699123
Lumbar vertebral fracture 56.60 13.04 27 14525 6995 79722841
Transient ischaemic attack 54.13 13.04 57 14495 52638 79677198
Retinal vein occlusion 54.06 13.04 21 14531 3302 79726534
Pelvic fracture 52.89 13.04 31 14521 12173 79717663
Endometrial cancer stage I 51.89 13.04 11 14541 188 79729648
Spinal fracture 51.04 13.04 35 14517 18019 79711817
Compression fracture 49.52 13.04 24 14528 6436 79723400
Fall 48.95 13.04 197 14355 487432 79242404
Toxicity to various agents 48.77 13.04 9 14543 421531 79308305
Wrist fracture 48.31 13.04 29 14523 11892 79717944
Off label use 46.07 13.04 59 14493 907156 78822680
Breast cancer in situ 43.36 13.04 13 14539 933 79728903
Product complaint 42.83 13.04 28 14524 13321 79716515
Visual acuity reduced 41.72 13.04 38 14514 29431 79700405
Cerebrovascular accident 41.32 13.04 89 14463 155203 79574633
Postmenopausal haemorrhage 40.90 13.04 14 14538 1538 79728298
Hot flush 37.29 13.04 48 14504 54829 79675007
Multiple fractures 36.40 13.04 21 14531 8005 79721831
Muscle spasms 35.39 13.04 90 14462 174640 79555196
Osteonecrosis of jaw 34.50 13.04 41 14511 43185 79686651
Ovarian cancer 34.39 13.04 16 14536 3918 79725918
Endometrial cancer stage II 33.67 13.04 5 14547 7 79729829
Uterine polyp 33.01 13.04 12 14540 1572 79728264
Injection site haemorrhage 31.97 13.04 32 14520 27838 79701998
Osteonecrosis 30.80 13.04 33 14519 31062 79698774
Uterine cancer 29.16 13.04 14 14538 3677 79726159
Drug ineffective 28.30 13.04 102 14450 1080811 78649025
Bone pain 26.36 13.04 41 14511 55701 79674135
Oedema peripheral 26.09 13.04 103 14449 252185 79477651
Feeling abnormal 25.26 13.04 75 14477 159124 79570712
Cerebral infarction 25.03 13.04 36 14516 45640 79684196
Completed suicide 23.10 13.04 8 14544 245759 79484077
Infusion related reaction 22.51 13.04 7 14545 230230 79499606
Hyperlipidaemia 21.23 13.04 25 14527 26068 79703768
Product use issue 21.20 13.04 6 14546 209816 79520020
Blindness unilateral 21.17 13.04 15 14537 8131 79721705
Death 21.07 13.04 45 14507 566469 79163367
Cataract 20.55 13.04 39 14513 62081 79667755
Myocardial infarction 20.52 13.04 77 14475 184052 79545784
Low turnover osteopathy 20.28 13.04 9 14543 1977 79727859
Blood calcium increased 20.02 13.04 16 14536 10384 79719452
Back pain 19.49 13.04 108 14444 304072 79425764
Ischaemic stroke 19.47 13.04 27 14525 33104 79696732
Diverticulum 18.75 13.04 18 14534 14878 79714958
Fractured sacrum 18.57 13.04 8 14544 1635 79728201
Intentional product use issue 18.10 13.04 3 14549 152109 79577727
Intestinal pseudo-obstruction 17.93 13.04 9 14543 2600 79727236
Intervertebral disc degeneration 17.87 13.04 18 14534 15767 79714069
Endometrial hyperplasia 17.79 13.04 6 14546 630 79729206
Injection site erythema 17.64 13.04 42 14510 78155 79651681
General physical health deterioration 17.14 13.04 15 14537 275223 79454613
Atrophic vulvovaginitis 17.14 13.04 7 14545 1254 79728582
Uterine leiomyoma 17.06 13.04 12 14540 6431 79723405
Stress fracture 16.99 13.04 12 14540 6468 79723368
Treatment failure 16.99 13.04 5 14547 170481 79559355
Drug intolerance 16.93 13.04 14 14538 264105 79465731
Retinal haemorrhage 16.58 13.04 13 14539 8204 79721632
Insulinoma 16.47 13.04 4 14548 128 79729708
Femoral neck fracture 16.38 13.04 14 14538 9970 79719866
Foot fracture 16.15 13.04 20 14532 21961 79707875
Synovitis 15.81 13.04 4 14548 150730 79579106
Acute kidney injury 15.61 13.04 46 14506 519358 79210478
Osteomyelitis 15.29 13.04 24 14528 32841 79696995
Rib fracture 15.27 13.04 22 14530 27925 79701911
Product use in unapproved indication 15.16 13.04 14 14538 250345 79479491
Endometrial hypertrophy 15.16 13.04 4 14548 180 79729656
Dementia Alzheimer's type 15.03 13.04 6 14546 1013 79728823
Jaw disorder 14.85 13.04 10 14542 4996 79724840
Erythema multiforme 14.51 13.04 17 14535 17634 79712202
Therapeutic product effect incomplete 14.40 13.04 4 14548 141641 79588195
Tibia fracture 14.23 13.04 10 14542 5351 79724485
Vascular headache 14.17 13.04 3 14549 51 79729785
Breast cancer recurrent 14.06 13.04 8 14544 2969 79726867
Osteoporotic fracture 13.86 13.04 9 14543 4231 79725605
Benign vulval neoplasm 13.75 13.04 3 14549 59 79729777
Fibrocystic breast disease 13.68 13.04 5 14547 665 79729171
Bone disorder 13.42 13.04 17 14535 19096 79710740
Breast swelling 13.28 13.04 6 14546 1374 79728462
Thrombotic stroke 13.12 13.04 5 14547 746 79729090

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03XC01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Selective estrogen receptor modulators
FDA MoA N0000000168 Selective Estrogen Receptor Modulators
CHEBI has role CHEBI:50646 antiosteoporotic
CHEBI has role CHEBI:50837 oestrogen antagonist
FDA EPC N0000175826 Estrogen Agonist/Antagonist
MeSH PA D050071 Bone Density Conservation Agents
MeSH PA D004965 Estrogen Antagonists
MeSH PA D020847 Estrogen Receptor Modulators
MeSH PA D006727 Hormone Antagonists
MeSH PA D020845 Selective Estrogen Receptor Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postmenopausal osteoporosis indication 102447009
Prevention of Breast Carcinoma indication
Prevention of Glucocorticoid-Induced Osteoporosis off-label use
Lupus anticoagulant disorder contraindication 19267009
Hypertensive disorder contraindication 38341003 DOID:10763
Thrombosis of retinal vein contraindication 46085004
Chronic heart failure contraindication 48447003
Atrial fibrillation contraindication 49436004 DOID:0060224
Thrombophlebitis contraindication 64156001 DOID:3875
Deep venous thrombosis contraindication 128053003
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.13 acidic
pKa2 8.6 acidic
pKa3 9.15 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor beta Nuclear hormone receptor MODULATOR EC50 8 WOMBAT-PK CHEMBL
Estrogen receptor Nuclear hormone receptor ANTAGONIST IC50 9.40 WOMBAT-PK IUPHAR
D(2) dopamine receptor GPCR Ki 6.41 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.93 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.21 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.42 CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 9 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.72 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.55 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.38 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.16 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.21 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.30 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 5.77 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.28 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 8.54 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 6.52 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.97 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.83 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor EC50 4.93 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 6.32 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 6.19 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.63 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 6.40 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 5.70 DRUG MATRIX
G-protein coupled estrogen receptor 1 GPCR EC50 6.50 WOMBAT-PK
Interleukin-6 Cytokine IC50 8.05 WOMBAT-PK
Tyrosine-protein kinase Fyn Kinase IC50 5.44 DRUG MATRIX
Bile acid receptor Nuclear hormone receptor IC50 4.94 CHEMBL
Substance-K receptor GPCR Ki 5.88 DRUG MATRIX
Phospholipase D1 Enzyme IC50 5.40 CHEMBL
Phospholipase D2 Enzyme IC50 5.47 CHEMBL
Lysine-specific histone demethylase 1A Enzyme IC50 5.68 CHEMBL
Complement C5 Secreted Kd 6.15 CHEMBL
Mu-type opioid receptor GPCR Ki 6.32 DRUG MATRIX
HLA class I histocompatibility antigen, A-3 alpha chain Unclassified Kd 4.66 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.71 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 5.83 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 6.07 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.63 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.66 CHEMBL
Estrogen receptor Transcription factor Ki 9.43 CHEMBL
Estrogen receptor beta Transcription factor Ki 8.56 CHEMBL
C-8 sterol isomerase Enzyme Ki 7.18 CHEMBL
Cruzipain Enzyme IC50 4.48 CHEMBL
Estrogen receptor Transcription factor IC50 8.73 CHEMBL

External reference:

IDSource
4024098 VUID
N0000022103 NUI
D02217 KEGG_DRUG
82640-04-8 SECONDARY_CAS_RN
4021080 VANDF
4024098 VANDF
C0244404 UMLSCUI
CHEBI:8772 CHEBI
RAL PDB_CHEM_ID
CHEMBL81 ChEMBL_ID
CHEMBL1116 ChEMBL_ID
D020849 MESH_DESCRIPTOR_UI
DB00481 DRUGBANK_ID
2820 IUPHAR_LIGAND_ID
5388 INN_ID
YX9162EO3I UNII
5035 PUBCHEM_CID
166551 RXNORM
11500 MMSL
5410 MMSL
83711 MMSL
d04261 MMSL
007282 NDDF
007283 NDDF
109029006 SNOMEDCT_US
395856004 SNOMEDCT_US
419530003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Evista HUMAN PRESCRIPTION DRUG LABEL 1 0002-4184 TABLET 60 mg ORAL NDA 33 sections
Evista HUMAN PRESCRIPTION DRUG LABEL 1 0002-4184 TABLET 60 mg ORAL NDA 33 sections
Evista HUMAN PRESCRIPTION DRUG LABEL 1 0002-4184 TABLET 60 mg ORAL NDA 33 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7290 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7290 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5295 TABLET, FILM COATED 60 mg ORAL ANDA 20 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6902 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 16714-213 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 16714-213 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 31722-256 TABLET 60 mg ORAL ANDA 20 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-726 TABLET, FILM COATED 60 mg ORAL ANDA 31 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 43353-253 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43598-505 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43598-505 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3363 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3866 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-5458 TABLET 60 mg ORAL ANDA 27 sections
Raloxifene hydrochloride Human Prescription Drug Label 1 50090-6177 TABLET, COATED 60 mg ORAL ANDA 28 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50228-306 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50228-306 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-694 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Evista HUMAN PRESCRIPTION DRUG LABEL 1 54868-4170 TABLET 60 mg ORAL NDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60687-266 TABLET 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60687-266 TABLET 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-7708 TABLET 60 mg ORAL ANDA 27 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-8209 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-057 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-057 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-057 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 65862-709 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections